I think it's very interesting looking at the Phase 0 opportunities with Novogen.
Firstly, their drugs fall under platforms (ie the ATM platform).
Prove the safety of 1 drug within the platform (ie the GBM collaboration with Feinstein, whose intent is to fast track to the clinic), and then Phase 0 can be applied for the remainder of the drugs under the platform.
Newsflow would then be aggressive IMO.
I think it's very interesting looking at the Phase 0...
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)